Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide-human leukocyte antigen (HLA) complexes represent a class of therapeutic targets consisting of processed peptides from the intracellular EBNA1 protein presented on the cell surface by HLA class I or class II molecules. EBNA1 is a multifunctional viral protein essential for the replication, partitioning, and maintenance of the EBV episome during latent infection, and it is expressed in all EBV-associated malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, Burkitt's lymphoma, and EBV-positive gastric cancer. Because EBNA1 is an intracellular protein, it cannot be targeted by conventional monoclonal antibodies; however, its degradation products are presented as peptide-HLA complexes on the cell surface, making them accessible to T-cell receptor (TCR)-engineered T cells (TCR-T) and TCR-like monoclonal antibodies. Therapies targeting these complexes, such as the TCR-T cell product YT-E001 and TCR-like antibodies like E1, aim to selectively eliminate EBV-infected or malignant cells while sparing healthy tissues. A major therapeutic challenge and safety concern is the potential for cross-reactivity and molecular mimicry, as EBNA1-derived peptides have been implicated in autoimmune diseases like multiple sclerosis through cross-reactivity with central nervous system antigens such as GlialCAM.
TCR-T cell therapy or TCR-like monoclonal antibodies bind to the EBNA1-derived peptide-HLA complexes on the surface of EBV-infected or malignant cells, triggering T-cell activation or antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to selectively destroy the target cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complexes (EBNA1-peptide-HLA complexes).